GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (NAS:KMDA) » Definitions » Cyclically Adjusted Price-to-FCF

KMDA (Kamada) Cyclically Adjusted Price-to-FCF : 39.00 (As of May. 25, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Kamada Cyclically Adjusted Price-to-FCF?

As of today (2025-05-25), Kamada's current share price is $6.63. Kamada's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was $0.17. Kamada's Cyclically Adjusted Price-to-FCF for today is 39.00.

The historical rank and industry rank for Kamada's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

KMDA' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 36   Med: 102.05   Max: 2005
Current: 39.07

During the past years, Kamada's highest Cyclically Adjusted Price-to-FCF was 2005.00. The lowest was 36.00. And the median was 102.05.

KMDA's Cyclically Adjusted Price-to-FCF is ranked worse than
59.81% of 316 companies
in the Drug Manufacturers industry
Industry Median: 30.61 vs KMDA: 39.07

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Kamada's adjusted free cash flow per share data for the three months ended in Mar. 2025 was $-0.035. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.17 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Kamada Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Kamada's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Cyclically Adjusted Price-to-FCF Chart

Kamada Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 508.56 133.79 37.39

Kamada Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.97 58.49 36.56 37.39 39.70

Competitive Comparison of Kamada's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kamada's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kamada's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Kamada's Cyclically Adjusted Price-to-FCF falls into.


;
;

Kamada Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Kamada's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=6.63/0.17
=39.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kamada's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Kamada's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.035/134.9266*134.9266
=-0.035

Current CPI (Mar. 2025) = 134.9266.

Kamada Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.172 100.684 -0.230
201509 -0.042 100.392 -0.056
201512 -0.169 99.792 -0.229
201603 0.173 100.470 0.232
201606 -0.178 101.688 -0.236
201609 -0.061 101.861 -0.081
201612 0.045 101.863 0.060
201703 0.007 102.862 0.009
201706 -0.040 103.349 -0.052
201709 -0.056 104.136 -0.073
201712 0.053 104.011 0.069
201803 0.124 105.290 0.159
201806 -0.087 106.317 -0.110
201809 0.013 106.507 0.016
201812 0.147 105.998 0.187
201903 0.140 107.251 0.176
201906 0.154 108.070 0.192
201909 0.129 108.329 0.161
201912 0.188 108.420 0.234
202003 -0.065 108.902 -0.081
202006 0.279 108.767 0.346
202009 -0.085 109.815 -0.104
202012 0.234 109.897 0.287
202103 0.044 111.754 0.053
202106 -0.098 114.631 -0.115
202109 -0.099 115.734 -0.115
202112 -0.141 117.630 -0.162
202203 0.108 121.301 0.120
202206 0.234 125.017 0.253
202209 0.080 125.227 0.086
202212 0.121 125.222 0.130
202303 -0.088 127.348 -0.093
202306 0.017 128.729 0.018
202309 -0.015 129.860 -0.016
202312 0.043 129.419 0.045
202403 -0.028 131.776 -0.029
202406 0.198 132.554 0.202
202409 0.364 133.029 0.369
202412 0.121 133.157 0.123
202503 -0.035 134.927 -0.035

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kamada  (NAS:KMDA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Kamada Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Kamada's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Kamada Business Description

Industry
Traded in Other Exchanges
Address
2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.